BRISBANE, Calif., Oct. 6 /PRNewswire-FirstCall/ -- InterMune, Inc. today announced that it will release third quarter 2006 financial results on Thursday, October 26, 2006 at 4:00 p.m. ET. The Company will host a live conference call and webcast at 4:30 p.m. ET that same day.
To access the live teleconference, dial 888-799-0528 (U.S.) or 706-634-0154 (international), conference ID# 8229882. To access the webcast, please log on to the Company’s website at www.intermune.com at least 15 minutes prior to the start of the call to ensure adequate time for any software downloads that may be required.
A replay of the webcast and teleconference will be available approximately three hours after the call. The teleconference replay will be available for ten business days following the call and can be accessed by dialing 800-642-1687 (U.S.) or 706-645-9291 (international), and entering the conference ID# 8229882.
About InterMune
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a pipeline portfolio addressing idiopathic pulmonary fibrosis (IPF) and hepatitis C virus (HCV) infections. The pulmonology portfolio includes two Phase III programs evaluating possible therapeutic candidates for treatment of patients with IPF. The INSPIRE trial is evaluating Actimmune(R) (interferon gamma-1b) and the CAPACITY program is evaluating pirfenidone. The hepatology portfolio includes the lead HCV protease inhibitor compound ITMN-191, a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology. For additional information about InterMune and its R&D pipeline, please visit www.intermune.com.
InterMune, Inc.
CONTACT: InterMune, Inc. Investor Relations Dept, +1-415-466-2242, orir@intermune.com; or media, Pam Lord of Porter Novelli Life Sciences,+1-619-849-6003, or plord@pnlifesciences.com, for InterMune, Inc.
Web site: http://www.intermune.com/
